Gastric neuroendocrine tumors: management and challenges

References

• Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007;10(2):123–133.
   Google Scholar
• Oberndorfer S. Karzinoide tumoren des dunndarms [Carcinoid tumors of the small intestine]. Frank F Z Pathol. 1907;1:426–429. German [with English abstract].
   Google Scholar
• Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13–27.
   PubMed Web of Science ®Google Scholar
• Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC; 2010.
   Google Scholar
• Boyce M, Thomsen L. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol. 2015;50(5):550–559.
   PubMed Web of Science ®Google Scholar
• Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994–1006.
   PubMed Web of Science ®Google Scholar
• Borch K, Ahrén B, Ahlman H, Falkmer S, Granérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.
   Web of Science ®Google Scholar
• Rindi G, Bordi C, Rappel S, Rosa SL, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–172.
   PubMed Web of Science ®Google Scholar
• Nandy N, Hanson JA, Strickland RG, McCarthy DM. Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literatures. Dig Dis Sci. 2016;61(3):708–712.
   Web of Science ®Google Scholar
• Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumors. Aliment Pharmacol Ther. 2014;39(10):1071–1084.
   Web of Science ®Google Scholar
• Bordi C. Neuroendocrine pathology of the stomach: the Parma contribution. Endocr Pathol. 2014;25(2):171–180.
   Web of Science ®Google Scholar
• Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology. 1997;113(3):773–781.
   Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12(2):153–172.
   Web of Science ®Google Scholar
• Metz DC. Diagnosis of the Zollinger Ellison syndrome. Clin Gastroenterol Hepatol. 2012;10(2):126–130.
   Web of Science ®Google Scholar
• Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10(2):199–202.
   PubMed Web of Science ®Google Scholar
• Nikou GC, Toubanakis C, Nikolaou P, et al. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52(66):1668–1676.
   PubMedGoogle Scholar
• Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, et al. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013;48(5):273–279.
   PubMed Web of Science ®Google Scholar
• Cavallaro A, Zanghi A, Cavallaro M, et al. The role of 68-GA-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int J Surg. 2014;12 Suppl 1: S225–S231.
   Google Scholar
• Naswa N, Sharma P, Soundararajan R, et al. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging. 2013;38:552–560.
   Google Scholar
• Hope TA, Pampaloni MH, Nakakura E, et al. Simultaneous (68) Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015;40(6):1432–1440.
   Google Scholar
• Menda Y, O’Dorisio TM, Howe JR, et al. Localization of unknown primary site with 68Ga-DOTATOC PET/CT in patients with metastatic neuroendocrine tumor. J Nucl Med. 2017;58(7):1054–1057.
   Google Scholar
• Kulke MH, Shah MH, Benson AB, et al. National Comprehensive Cancer Network. Neuroendocrine tumors, version 3.2017. Available from: www.nccn.org. Accessed June 13, 2017.
   Google Scholar
• Delle Fave G, O’Toole D, Sundin A, et al; Vienna Consensus Conference participants. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–124.
   PubMed Web of Science ®Google Scholar
• Gorzinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013;19(46):8687–8695.
   Web of Science ®Google Scholar
• Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95(3):207–213.
   Web of Science ®Google Scholar
• Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol. 2014;109:71–74.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Ishii N, Uemura M, et al. Endoscopic submucosal dissection (ESD) for gastrointestinal carcinoid tumors. Surg Endosc. 2012;26(3):759–763.
   PubMed Web of Science ®Google Scholar
• Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009;15(1):1–16.
   PubMed Web of Science ®Google Scholar
• Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817–6828.
   PubMed Web of Science ®Google Scholar
• Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15(1):337–342.
   Web of Science ®Google Scholar
• Campana D, Ravizza D, Ferolla P, et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine. 2016;51(1):131–139.
   Web of Science ®Google Scholar
• Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006;93(5):368–372.
   Web of Science ®Google Scholar
• Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol. 2004;39(7):621–628.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008;159(4):475–482.
   Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46(4):456–463.
   PubMed Web of Science ®Google Scholar
• Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol. 2010;25(3):548–554.
   Web of Science ®Google Scholar
• Manfredi S, Pagenault M, de Lajarte-Thirouard AS, Bretagne JF. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol. 2007;19(11):1021–1025.
   PubMed Web of Science ®Google Scholar
• Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168(2):185–193.
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med. 2000;343(8):551–554.
   Web of Science ®Google Scholar
• Massironi S, Zilli A, Conte D. Somatostatin analogs for gastric carcinoids: for many, but not all. World J Gastroenterol. 2015;21(22):6785–6793.
   Web of Science ®Google Scholar
• Massironi S, Zilli A, Fanetti I, Ciafardini C, Conte D, Peracchi M. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Dig Liver Dis. 2015;47(11):978–983.
   Google Scholar
• Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol. 2009;15(18):2177–2183.
   Web of Science ®Google Scholar
• Fossmark R, Sørdal Ø, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36(11–12):1067–1075.
   PubMed Web of Science ®Google Scholar
• Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8(10):76462.
   Web of Science ®Google Scholar
• Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Oberg K. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43(2):223–228.
   Web of Science ®Google Scholar
• Kim SY, Woo IS, Yang JH, Han CW, Roh SY, Jung YH. A case of metastatic gastric neuroendocrine tumor: therapeutic considerations. Case Rep Oncol. 2014;7(1):266–272.
   Google Scholar
• Caplin ME, Hodgson HJ, Dhillon AP, et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol. 1998;93(10):1945–1948.
   Web of Science ®Google Scholar
• Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825.
   Web of Science ®Google Scholar
• Bongiovanni A, Riva N, Ricci M, et al. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. Onco Targets Ther. 2015;8:3613–3619.
   PubMed Web of Science ®Google Scholar
• Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14(2):161–165.
   Web of Science ®Google Scholar
• Yamaguchi T, Machida N, Morizane C, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105(9):1176–1181.
   PubMed Web of Science ®Google Scholar
• Postlewait LM, Baptiste GG, Ethun CG, et al. A 15-year experience with gastric neuroendocrine tumors: does type make a difference? J Surg Oncol. 2016;114(5):576–580.
   PubMed Web of Science ®Google Scholar
• Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154–3160.
   Web of Science ®Google Scholar
• Lahner E, Esposito G, Pilozzi E, et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol. 2015;50(7):856–865.
   PubMed Web of Science ®Google Scholar
• Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93(5):1582–1591.
   PubMed Web of Science ®Google Scholar
• Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267–1274.
   Web of Science ®Google Scholar
• Kidd M, Gustafsson B, Modlin IM. Gastric carcinoids (neuroendocrine neoplasms). Gastroenterol Clin North Am. 2013;42(2):381–397.
   PubMed Web of Science ®Google Scholar
• Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol. 2013;19(46):8703–8708.
   Web of Science ®Google Scholar